問卷

TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Pediatrics

MacKay Memorial Hospital

Division of Pediatrics

更新時間:2023-09-19

丁瑋信
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

14Cases

2017-04-01 - 2019-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-01-01 - 2025-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-11-02 - 2024-12-02

Phase III

Completed
PIONEER TEENS - Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes
  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Semaglutide

Participate Sites
2Sites

Recruiting2Sites

2019-01-01 - 2020-12-31

Others

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) Quadrivalent Inactivated Influenza Vaccine in Healthy Subjects Aged 6 Months Old to 35 Months Old
  • Condition/Disease

    Influenza

  • Test Drug

    AdimFlu-S Quadrivalent Inactivated Influenza Vaccine(AdimFlu-S(QIS))

Participate Sites
9Sites

Recruiting8Sites

2019-06-01 - 2021-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-09-30 - 2015-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-05-15 - 2019-05-31

Others

Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks.
  • Condition/Disease

    Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV).

  • Test Drug

    HRV PCV-free vaccine

Participate Sites
6Sites

Terminated6Sites

2016-03-01 - 2018-10-31

Phase II

A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine
  • Condition/Disease

    Active immunization against influenza A virus H5N1 subtype

  • Test Drug

    GlaxoSmithKline (GSK) Biologicals’ Influenza A/Indonesia/05/2005 (H5N1) vaccine adjuvanted with AS03

Participate Sites
8Sites

Terminated7Sites

2014-07-01 - 2017-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-12-01 - 2022-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator Controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU -LINK)
  • Condition/Disease

    Pneumococcal Infections

  • Test Drug

    15-Valent Pneumococcal Conjugate Vaccine (V114)

Participate Sites
4Sites

Terminated4Sites

1 2